.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SOLO1 trial evaluated maintenance olaparib in women with newly diagnosed advanced ovarian cancer carrying BRCA1 or BRCA2 mutations who had responded to platinum-based chemotherapy. Olaparib produced a major improvement in progression-free survival compared with placebo. The study established a new treatment paradigm in ovarian cancer in which molecular biomarkers influence maintenance therapy after initial response. For gynecologic oncologists, this means germline and tumor genetic testing can directly affect treatment planning. Counseling should include discussion of hereditary cancer implications, family testing and the long-term management of therapy-related adverse effects. The broader clinical message is that precision oncology depends on timely biomarker identification and integration of molecular results into the treatment pathway rather than using targeted therapies only after multiple lines of chemotherapy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SOLO1 trial evaluated maintenance olaparib in women with newly diagnosed advanced ovarian cancer carrying BRCA1 or BRCA2 mutations who had responded to platinum-based chemotherapy. Olaparib produced a major improvement in progression-free survival compared with placebo. The study established a new treatment paradigm in ovarian cancer in which molecular biomarkers influence maintenance therapy after initial response. For gynecologic oncologists, this means germline and tumor genetic testing can directly affect treatment planning. Counseling should include discussion of hereditary cancer implications, family testing and the long-term management of therapy-related adverse effects. The broader clinical message is that precision oncology depends on timely biomarker identification and integration of molecular results into the treatment pathway rather than using targeted therapies only after multiple lines of chemotherapy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
